Keywords: Swedish Orphan Biovitrum, Kineret, NOMID, USA, FDA, SOBI

FDA approves SOBI's Kineret for the treatment of NOMID

Article | 08 January 2013

Print This

Biotech firm Swedish Orphan Biovitrum (STO: SOBI) today announced that the US Food and Drug Administration has approved Kineret (anakinra) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in